S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:HILS

Hillstream BioPharma (HILS) Stock Forecast, Price & News

$0.37
+0.02 (+5.64%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.35
$0.37
50-Day Range
$0.35
$1.09
52-Week Range
$0.30
$2.65
Volume
199,464 shs
Average Volume
720,048 shs
Market Capitalization
$4.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Hillstream BioPharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
7.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Hillstream BioPharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.27) to ($0.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.25 out of 5 stars


HILS stock logo

About Hillstream BioPharma (NASDAQ:HILS) Stock

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Receive HILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HILS Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Hillstream Nearly Doubles on Test Results
See More Headlines
Receive HILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HILS Company Calendar

Today
5/28/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HILS
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Net Income
$-8,470,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.28 per share

Miscellaneous

Free Float
6,897,000
Market Cap
$4.31 million
Optionable
Not Optionable
Beta
3.25

Key Executives

  • Mr. Randy D. Milby MBA (Age 69)
    Pres, Chairman & CEO
  • Mr. Thomas P. Hess CPA (Age 59)
    MBA, Chief Financial Officer













HILS Stock - Frequently Asked Questions

Should I buy or sell Hillstream BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HILS shares.
View HILS analyst ratings
or view top-rated stocks.

How have HILS shares performed in 2023?

Hillstream BioPharma's stock was trading at $0.3898 at the start of the year. Since then, HILS stock has decreased by 3.9% and is now trading at $0.3745.
View the best growth stocks for 2023 here
.

Are investors shorting Hillstream BioPharma?

Hillstream BioPharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 263,600 shares, an increase of 60.8% from the April 30th total of 163,900 shares. Based on an average trading volume of 682,400 shares, the short-interest ratio is currently 0.4 days. Currently, 7.4% of the shares of the stock are short sold.
View Hillstream BioPharma's Short Interest
.

When is Hillstream BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HILS earnings forecast
.

When did Hillstream BioPharma IPO?

(HILS) raised $21 million in an initial public offering (IPO) on Wednesday, January 12th 2022. The company issued 3,750,000 shares at $5.00-$6.00 per share.

What is Hillstream BioPharma's stock symbol?

Hillstream BioPharma trades on the NASDAQ under the ticker symbol "HILS."

Who are Hillstream BioPharma's major shareholders?

Hillstream BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.33%).
View institutional ownership trends
.

How do I buy shares of Hillstream BioPharma?

Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hillstream BioPharma's stock price today?

One share of HILS stock can currently be purchased for approximately $0.37.

How much money does Hillstream BioPharma make?

Hillstream BioPharma (NASDAQ:HILS) has a market capitalization of $4.31 million.

How can I contact Hillstream BioPharma?

The official website for the company is www.hillstreambio.com. The company can be reached via phone at 908-955-3140 or via email at investorrelations@hillstreambio.com.

This page (NASDAQ:HILS) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -